NICE Rejects Donanemab for NHS Use Due to Cost Concerns

By João L. Carapinha

October 24, 2024

The article from the National Institute for Health and Care Excellence (NICE) on the new Alzheimer’s treatment donanemab highlights several key points regarding the decision not to recommend this drug for use in the NHS. Essentially, donanemab has faced rejection due to concerns over its cost-effectiveness and the limited benefits it provides.

Reason for the Donanemab NHS rejection

NICE has determined that donanemab “does not currently demonstrate value for the NHS.” The NHS based this decision primarily on the drug’s cost-effectiveness; they saw its benefits to patients as too minimal to warrant the significant additional costs. The cost-effectiveness estimate for donanemab is five to six times above the threshold that NICE typically considers acceptable for NHS resources.

Clinical Benefits

While donanemab, manufactured by Eli Lilly, has shown potential to slow cognitive decline in Alzheimer’s patients, the observed benefits are relatively small. Clinical trials indicate that donanemab could result in a delay of cognitive decline by four to seven months. However, NICE’s independent committee concluded that this improvement is not adequate to justify the high costs associated with the treatment.

Regulatory Approval

Despite NICE’s decision, donanemab has received approval from the UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for use within the UK. This approval is significant as it highlights the drug’s safety and efficacy, but it does not change NICE’s assessment regarding its cost-effectiveness for NHS use.

Impact on Patients and Carers

The rejection of donanemab for NHS use is a considerable setback for patients with early-stage Alzheimer’s and their carers. Advocates argue that drugs like donanemab, along with another rejected treatment called lecanemab, represent the first chance to effectively slow the decline in memory and cognitive abilities associated with Alzheimer’s, rather than merely addressing symptoms. Consequently, the decision may restrict access to these therapies to individuals who can afford private treatment.

Future Implications

This decision raises alarms that the UK could become a less appealing market for launching new dementia treatments due to strict cost-effectiveness standards. Organizations such as Alzheimer’s Research UK and various charities have urged the Health Secretary to take action and initiate discussions among NICE, NHS England, and the pharmaceutical industry. Policymakers aim to ensure that patients with dementia can access new treatments and receive proper attention in the healthcare system.

Ongoing Research and Development

NICE acknowledges that this is an emerging area of medicine and that further treatments are currently being researched. The agency emphasizes that more comprehensive evidence is needed on the clinical and cost-effectiveness of donanemab, suggesting that future reassessments could occur if additional data become available.

Reference url

Recent Posts

pharmaceutical industry Europe
    

Pharmaceutical Industry Europe: Key Insights and Future Challenges for 2025

💡 How is the pharmaceutical industry in Europe poised to navigate the challenges of 2025?

As the industry faces fierce competition, regulatory hurdles, and evolving market dynamics, this article provides key insights into R&D investments, employment trends, and the urgent need for policy reforms. Discover how Europe can leverage its strengths to maintain its leadership in global life sciences.

Jump into these pivotal developments and strategies by reading the full article!

#SyenzaNews #pharmaceuticals #healthcarepolicy

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.